By David Wahlberg, The Atlanta Journal-Constitution Knight Ridder/Tribune Business News
May 14--An experimental drug for the common cold could be a starting point for finding a treatment for SARS, German researchers said Tuesday.
The drug, made by Pfizer and known only as AG-7088, is in clinical trials.
It attacks the rhinovirus, a cause of colds, by blocking an enzyme the virus needs to replicate itself. The enzyme, called "protease," is targeted --- in a slightly different way --- in AIDS drugs known as protease inhibitors.
AG-7088 could be modified to attack the coronavirus that causes SARS, scientists from the University of Lubeck …